Steve E Kalloger
Overview
Explore the profile of Steve E Kalloger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
5113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kalloger S, Watson A, Sajkowski S, Warwick L
Cancer Res Commun
. 2024 Jun;
4(6):1561-1565.
PMID: 38837892
Significance: CRF is a highly incident phenomenon in lymphoma that can be ascribed to a combination of causes. We have demonstrated substantial variability across various subtypes of lymphoma and have...
2.
Sathiyaseelan P, Chittaranjan S, Kalloger S, Chan J, Go N, Jardon M, et al.
J Cell Sci
. 2023 Sep;
136(19).
PMID: 37701987
Pancreatic ductal adenocarcinoma (PDAC) exhibits elevated levels of autophagy, which promote tumor progression and treatment resistance. ATG4B is an autophagy-related cysteine protease under consideration as a potential therapeutic target, but...
3.
Topham J, Tsang E, Karasinska J, Metcalfe A, Ali H, Kalloger S, et al.
Nat Commun
. 2022 Oct;
13(1):5941.
PMID: 36209277
Oncogenic KRAS mutations are absent in approximately 10% of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and may represent a subgroup of mPDAC with therapeutic options beyond standard-of-care cytotoxic chemotherapy....
4.
Mapping the experiences of people with advanced cancer across multiple cancer types-a scoping review
Kalloger S, Ho C, Mitton C, Regier D
J Cancer Surviv
. 2022 Sep;
18(2):318-324.
PMID: 36180762
Background: Through the introduction of tumor agnostic therapies, people with metastatic cancer and their treating physicians are facing new treatment choices that have differing side effect and efficacy profiles from...
5.
Kalloger S, Karasinska J, Warren C, Renouf D, Schaeffer D
Biomark Insights
. 2021 Oct;
16:11772719211049852.
PMID: 34658620
Biobanking efforts, to establish and grow the pool of available tissue from which evidence on aetiology, therapeutic susceptibility and prognosis of various diseases, have been underway for decades. This is...
6.
Yang K, Kalloger S, Aird J, Lee M, Rushton C, Mungall K, et al.
Cell Rep
. 2021 Oct;
37(2):109817.
PMID: 34644566
Pancreatic neuroendocrine neoplasms (PNENs) are biologically and clinically heterogeneous. Here, we use a multi-omics approach to uncover the molecular factors underlying this heterogeneity. Transcriptomic analysis of 84 PNEN specimens, drawn...
7.
Dixon K, Brew T, Farnell D, Godwin T, Cheung S, Chow C, et al.
J Pathol
. 2021 Apr;
254(3):254-264.
PMID: 33797756
Hereditary diffuse gastric cancer (HDGC) is a cancer syndrome caused by germline variants in CDH1, the gene encoding the cell-cell adhesion molecule E-cadherin. Loss of E-cadherin in cancer is associated...
8.
Naso J, Topham J, Karasinska J, Lee M, Kalloger S, Wong H, et al.
Cancer Med
. 2020 Dec;
10(3):1155-1165.
PMID: 33372414
Background: RNA-sequencing-based classifiers can stratify pancreatic ductal adenocarcinoma (PDAC) into prognostically significant subgroups but are not practical for use in clinical workflows. Here, we assess whether histomorphological features may be...
9.
Topham J, Karasinska J, Lee M, Csizmok V, Williamson L, Jang G, et al.
Clin Cancer Res
. 2020 Oct;
27(1):150-157.
PMID: 33051307
Purpose: RNA-sequencing-based subtyping of pancreatic ductal adenocarcinoma (PDAC) has been reported by multiple research groups, each using different methodologies and patient cohorts. "Classical" and "basal-like" PDAC subtypes are associated with...
10.
Tsang E, Topham J, Karasinska J, Lee M, Williamson L, Mendis S, et al.
Clin Cancer Res
. 2020 Sep;
27(1):246-254.
PMID: 32958704
Purpose: With the rising incidence of early-onset pancreatic cancer (EOPC), molecular characteristics that distinguish early-onset pancreatic ductal adenocarcinoma (PDAC) tumors from those arising at a later age are not well...